[{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Ferndale Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CTX-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Crescita Therapeutics \/ Ferndale Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Crescita Therapeutics \/ Ferndale Laboratories"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Both studies of CTX-101 met the primary endpoint for psoriasis, CTX-101 is a topical formulation utilizing a corticosteroid in combination with our patented MMPE technology

                          Product Name : CTX-101

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 02, 2020

                          Lead Product(s) : CTX-101

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Ferndale Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank